abrdn Life Sciences Investors Q1 2025 Commentary
Source: SeekingAlpha
2025-05-31 00:20:00 ET
Summary
- The equity portion of the Fund fell (gross of fees) and underperformed its benchmark, the NASDAQ Biotechnology Index.
- During the first quarter of 2025, we made several changes to the portfolio.
- With Donald Trump securing his second term, uncertainty around election results has been replaced with policy ambiguity.
Fund performance
Read the full article on Seeking Alpha
For further details see:
abrdn Life Sciences Investors Q1 2025 Commentary
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-5.35% G/L:
$53.39 Last:
575,994 Volume:
$57.06 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
